Le Lézard
Classified in: Health, Science and technology
Subject: PLW

Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENTtm

SANTA BARBARA, Calif., Jan. 9, 2023 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent 11,534,454 titled Complexing Agent Salt Formulations of Pharmaceutical Compounds.

Bexson's formulation technology, branded as SEVALENTtm, is the basis for the Company's lead therapy utilizing ketamine for post-operative pain management.  This patent now expands the potential utility of its technology to a broad range of additional small molecules enabling intravenous (IV)-only therapies to be delivered subcutaneously in a controlled manner for use in the home setting.

"This patent is critical in protecting our novel salt formulation, SEVALENTtm, across an extensive range of therapeutic areas," commented Jeffrey Becker, MD, Chief Scientific Officer.  "We believe SEVALENTtm creates the opportunity to migrate a wide variety of small molecule therapies from IV to subcutaneous administration which will be a game changer for both patients and payors."

"We are pleased with this step forward in building out the Company's patent portfolio and achieving another important milestone in protecting our formulation technology," said Gregg Peterson, CEO.  "In addition, this patent further strengthens our intellectual property position and underscores our strong commitment to innovation in advancing subcutaneous delivery of small molecule therapies."

Bexson Biomedical, Inc.

Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions through new formulations designed for subcutaneous delivery. Bexson's proprietary platform, SEVALENTtm, can be applied to small molecules across a broad range of drug classes, enabling IV therapies to be delivered subcutaneously.

Bexson's lead therapy, BB106, is a low-dose ketamine treatment for post-operative pain management, a $36B global market and leading driver of opioid addiction. Additionally, management believes its BB106 formulation technology can be utilized to address various mental health indications.

SOURCE Bexson Biomedical

These press releases may also interest you

at 18:00
Aurora Cannabis Inc. ("Aurora" or the "Company") , the Canadian company opening the world to cannabis, today announced receipt of a notification letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") dated March 24, 2023,...

at 17:30
Cybeats Technologies Corp. ("Cybeats'' or the "Company") is pleased to announce the commencement of a trial evaluation with one of the top-3 largest software companies by total revenue, for Cybeats SBOM Studio.1...

at 17:30
Western University of Health Sciences' College of Osteopathic Medicine of the Pacific (COMP) and COMP-Northwest celebrated 100% residency placement on Match Day, compared to the averages across all other medical schools with match rates of 91.6% for...

at 17:00
Andlauer Healthcare Group Inc. ("AHG" or the "Company") today announced that the Toronto Stock Exchange has approved its notice of intention to make a normal course issuer bid for a portion of its subordinate voting shares ("Shares") as appropriate...

at 17:00
Pieris Pharmaceuticals, Inc. ,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host...

at 16:35
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the full year ended December 31, 2022, and provided a corporate...

News published on 9 january 2023 at 13:41 and distributed by: